<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163270">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972725</url>
  </required_header>
  <id_info>
    <org_study_id>113165</org_study_id>
    <nct_id>NCT00972725</nct_id>
  </id_info>
  <brief_title>Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose</brief_title>
  <official_title>A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and reactogenicity of one booster dose
      of a HIV candidate vaccine after administration of one oral dose of chloroquine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated following Protocol amendment 1, October 2009.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cellular immune response to components of the study vaccine</measure>
    <time_frame>At Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of solicited local and general symptoms</measure>
    <time_frame>During a 7-day (Day 0-6) follow-up period after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited symptoms</measure>
    <time_frame>During a 30-day (Day 0-29) follow-up period after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse event</measure>
    <time_frame>From the beginning up to the study end (Day 0-180)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse event of specific interest, including Immune-Mediated Disorders (IMD)</measure>
    <time_frame>From the beginning up to the study end (Day 0-180)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Haematological and biochemical levels</measure>
    <time_frame>At Days 0, 7, 30 and 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular and humoral immune response to components of the candidate vaccines in all subjects</measure>
    <time_frame>At Days 0, 7, 14, 30 and 180</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Immunologic Tests</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' HIV vaccine (732461)</intervention_name>
    <description>1 dose intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>One dose of 300 mg</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Nivaquine®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female between, and including, 18 to 52 years of age at the time of
             vaccination.

          -  Written informed consent prior to any study related procedure on the subject.

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  Good general health without significant medical history or physical examination
             findings.

          -  Negative for anti-HBc and anti-Hepatitis C Virus antibodies.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  has practiced adequate contraception for 30 days prior to vaccination, and

          -  has a negative pregnancy test on the day of vaccination, and

          -  has agreed to continue adequate contraception until study completion.

          -  Previous participation and completion of the study NCT00434512.

          -  Cellular and humoral immune responder to vaccines administered in study NCT00434512.

          -  Subjects must be willing to accept HIV test results. Individuals who elect not to
             receive test results will not be enrolled.

        Exclusion Criteria:

          -  Clinically significant laboratory value above normal range for blood urea nitrogen,
             creatinine, alanine aminotransferase and aspartate aminotransferase, or clinically
             significant laboratory value above or below normal range for Hemoglobin, as per
             investigator judgment.

          -  Women who are pregnant or breast-feeding.

          -  Receipt of live attenuated vaccines within 30 days of vaccination.

          -  Receipt of medically indicated subunit or killed vaccines (e.g., influenza,
             pneumococcal) or allergy treatment with antigen injections (including a tuberculin
             skin test) within &lt;= 21days preceding and planned &lt;= 21 days following the study
             vaccine administration.

          -  Receipt of blood products 120 days prior to vaccination.

          -  Receipt of immunoglobulin 120 days prior to vaccination.

          -  Subject has donated blood in the last 3 months.

          -  Bleeding disorder that was diagnosed by a physician; e.g., factor deficiency,
             coagulopathy or platelet disorder that requires special precautions.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first.

          -  History of serious adverse reactions to vaccines including anaphylaxis and related
             symptoms such as hives, respiratory difficulty, angioedema and abdominal pain.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine/product.

          -  History of serious allergic reaction to any substance requiring hospitalization or
             emergency medical care.

          -  History of hypersensitivity against chloroquine or any components of the drug.

          -  History of hypersensitivity against aminoglycosides.

          -  Ophthalmologic findings at screening.

          -  Previous administration of 4-aminoquinoline in the previous year or for a duration of
             more than 1 year.

          -  History of Glucose-6-Phosphate Dehydrogenase deficiency.

          -  History of hematopoietic disease.

          -  History of Myasthenia gravis.

          -  History of any serious neurological disorder or seizure.

          -  History of immunodeficiency or immune-mediated disorders, including active psoriasis.

          -  History of type I or type II diabetes mellitus including cases controlled with diet
             alone.

          -  Thyroid disease including history of thyroidectomy and diagnoses requiring
             medication.

          -  Asthma requiring daily steroid or long acting β-agonist prevention.

          -  Unstable asthma defined as:

          -  Sudden acute attacks occurring in less than three hours without an obvious trigger.

          -  Hospitalization for asthma in the last two years.

          -  Food- or wine-induced asthma.

          -  Known sensitivity to sulfites or aspirin.

          -  History of major congenital defect.

          -  History of chronic fatigue syndrome or fibromyalgia.

          -  History of malignancy.

          -  Splenectomy.

          -  Morbid obesity.

          -  Clinically relevant hypertension.

          -  Subjects with a history of, or current, alcohol or substance abuse.

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the first dose of study vaccines, or planned use during the
             study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Previous inclusion in a HIV vaccines trial other than study NCT00434512.

          -  Subject is seropositive for HIV, as determined by the test results performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>January 22, 2011</lastchanged_date>
  <firstreceived_date>September 3, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>December 23, 2010</firstreceived_results_disposition_date>
  <responsible_party>
    <name_title>E.D. Derilus; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Chloroquine</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
